| Recruiting | Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS NCT06863142 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age NCT06602024 | ModernaTX, Inc. | Phase 3 |
| Completed | A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months NCT06049927 | Sinovac Biotech Co., Ltd | Phase 3 |
| Completed | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults NCT05827978 | ModernaTX, Inc. | Phase 3 |
| Completed | A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults NCT05827068 | ModernaTX, Inc. | Phase 1 / Phase 2 |
| Completed | Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated NCT05512494 | Sinovac Biotech Co., Ltd | Phase 4 |
| Completed | A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older NCT05566639 | ModernaTX, Inc. | Phase 3 |
| Completed | A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months NCT05245552 | Sinovac Biotech Co., Ltd | Phase 3 |
| Completed | Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent NCT05431725 | Sinovac Biotech Co., Ltd | Phase 3 |
| Completed | A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults NCT05415462 | ModernaTX, Inc. | Phase 3 |
| Completed | A Study of Modified mRNA Vaccines in Healthy Adults NCT05397223 | ModernaTX, Inc. | Phase 1 |
| Completed | A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults NCT05333289 | ModernaTX, Inc. | Phase 1 / Phase 2 |
| Completed | A Clinical Trial of Quadrivalent Influenza Vaccine in Children Aged 3-8 Years Old NCT04997239 | Sinovac Biotech Co., Ltd | Phase 4 |
| Completed | A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults NCT04956575 | ModernaTX, Inc. | Phase 1 / Phase 2 |
| Completed | First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated NCT04896086 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza NCT04133584 | Zhejiang Provincial Center for Disease Control and Prevention | Phase 4 |
| Completed | Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml) NCT03859141 | Sinovac Biotech Co., Ltd | Phase 3 |
| Completed | Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml) NCT03853993 | Sinovac Biotech Co., Ltd | Phase 3 |
| Completed | A Phase I Study of Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1 NCT01818362 | University of Oxford | Phase 1 |
| Completed | Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum NCT01761123 | Vaxart | Phase 1 |
| Completed | Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly S NCT01344057 | Novartis Vaccines | Phase 2 |
| Completed | Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventiona NCT01342796 | Novartis Vaccines | Phase 2 |
| Completed | Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children NCT01180621 | Dalhousie University | Phase 2 |
| Completed | Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Ad NCT01209780 | Novartis Vaccines | Phase 3 |
| Completed | Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, W NCT01161264 | Novartis Vaccines | Phase 3 |
| Completed | Yearly Strain Variation Study, 2010/2011 NCT01157702 | Alachua Government Services, Inc. | Phase 3 |
| Completed | Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011 NCT01147081 | Novartis Vaccines | Phase 3 |
| Completed | Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult a NCT01151059 | Novartis Vaccines | Phase 2 |
| Completed | Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly S NCT01152814 | Novartis Vaccines | Phase 2 |
| Completed | Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Vo NCT01123954 | Novartis Vaccines | Phase 2 |
| Terminated | A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standa NCT00958776 | BioCryst Pharmaceuticals | Phase 3 |
| Completed | Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal In NCT01011582 | Virginia Commonwealth University | — |
| Completed | The Effect of a Planning Prompt on Seasonal Influenza Vaccination Rates NCT01207232 | University of Pennsylvania | N/A |
| Completed | Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza NCT00957996 | BioCryst Pharmaceuticals | Phase 3 |
| Completed | Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine NCT01072799 | Novavax | Phase 2 |
| Completed | The Effect of Time-Slot Scheduling on Flu Vaccination Rates NCT01206686 | University of Pennsylvania | N/A |
| Completed | Yearly Strain Variation Study, 2009/2010 NCT00943657 | Alachua Government Services, Inc. | Phase 3 |
| Completed | Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, NCT00956449 | Novartis | Phase 2 |
| Completed | Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vacci NCT00956761 | Novartis | Phase 2 |
| Completed | Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010 NCT00945841 | Novartis | Phase 3 |
| Completed | Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine NCT00903552 | Novavax | Phase 2 |
| Completed | Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008 NCT00748813 | Novartis Vaccines | Phase 2 |
| Completed | Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults a NCT00560066 | Novartis Vaccines | Phase 4 |
| Completed | Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008 NCT00498303 | Novartis | Phase 3 |